We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Evaluate Kidney Injury in Cancer Patients

By LabMedica International staff writers
Posted on 17 Feb 2021
Print article
Image: Histopathology of drug-induced acute interstitial nephritis showing interstitial inflammation with prominent eosinophils and tubulitis (the presence of inflammatory cells within the tubular wall) (Photo courtesy of NephSim).
Image: Histopathology of drug-induced acute interstitial nephritis showing interstitial inflammation with prominent eosinophils and tubulitis (the presence of inflammatory cells within the tubular wall) (Photo courtesy of NephSim).
Immune checkpoint inhibitors (ICI) are monoclonal antibodies that can unleash the immune system by blocking surface molecules that serve as important breaks (or checkpoints) that mediate negative regulation of T cells. ICI have substantially improved the prognosis for patients with a wide range of malignancies.

ICI therapy may induce a variety of immune related adverse events (iRAEs), including nephrotoxicity. The incidence of iRAE in patients receiving ICI can be as high as 85% depending on the target and the use of mono- or combination therapy. The most commonly affected organs are skin, endocrine glands, gastrointestinal tract, lungs and liver.

Nephrologists at the Mayo Clinic (Rochester, MN, USA) carried out a single center, retrospective observational study. They performed a search of the electronic medical records for all patients who had received an ICI and suffered an acute kidney injury (AKI) event between January 2014 and June 2020. There were 37 patients with ICI-AKI and 13 non-ICI AKI referents in the cohort for analysis. Clinical and laboratory features, including serum creatinine (SCr), serum C-reactive protein (CRP) and urine retinol binding protein/ urine creatinine(uRBP/Cr) levels at AKI event were evaluated.

The scientists reported that At time of AKI, SCr, CRP and uRBP/Cr were significantly higher in the ICI-AKI compared to the non-ICI-AKI patients (median [IQR] serum creatinine 2.0 [1.7, 2.9] versus1.5 [1.3, 1.6] mg/dL, serum CRP 54.0 [33.7, 90.0] versus 3.5 [3.0, 7.9] mg/L and urine uRBP/Cr 1,927 [1,174, 46,522] versus 233 [127, 989] mcg/g Cr, respectively). Compared to the referent group, time from ICI initiation to AKI was shorter in the ICI-AKI patients. Among the ICI-AKI group, complete renal recovery occurred in 39% of patients by three months; rechallenge occurred in 16 (43%) of patients, of whom three (19%) had recurrence of AKI. A pattern was observed with eGFR, which decreased in the ICI-AKI group as compared to the non-ICI-AKI at the time of AKI (median 28.9 [16.7, 37.8] versus 40.6 [38.9, 46] mL/min/1.73m2, respectively.

Sandra M. Herrmann, MD, a Nephrologist and the study's senior author, said, “Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer. In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis.”

The authors concluded that their study provided novel, important data for clinicians regarding the use of biomarkers in the routine evaluation of cause of AKI in patients on ICI therapy. These biomarkers could assist with discriminating ICI-AKI from other causes and may also help aid clinical decision-making related to both management and recurrence. They also described distinguishing clinical characteristics of patients with ICI-AKI, which may help with the diagnosis and possible prevention of ICI-AKI, by reinforcing the strategy of avoidance of acute interstitial nephritis (AIN) associated drugs in this type of patient. The study was published on February 1, 2021 in the journal Kidney International Reports.

Related Links:
Mayo Clinic

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.